Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Insights, Forecast to 2028

Report ID: 1655093 | Published Date: Jan 2025 | No. of Page: 92 | Base Year: 2024 | Rating: 4.2 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Business Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 Oral Medications
        1.2.3 Temozolomide
        1.2.4 Radiosensitizers
        1.2.5 Nitrosoureas Drugs
        1.2.6 Radiation Therapy
        1.2.7 Chemotherapy
    1.3 Market by Application
        1.3.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Hospitals
        1.3.3 Clinics
        1.3.4 Ambulatory Surgical Centers
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Perspective (2017-2028)
    2.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Growth Trends by Region
        2.2.1 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Historic Market Size by Region (2017-2022)
        2.2.3 Recurrent Glioblastoma Multiforme (GBM) Treatment Forecasted Market Size by Region (2023-2028)
    2.3 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Dynamics
        2.3.1 Recurrent Glioblastoma Multiforme (GBM) Treatment Industry Trends
        2.3.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Drivers
        2.3.3 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Challenges
        2.3.4 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Recurrent Glioblastoma Multiforme (GBM) Treatment Players by Revenue
        3.1.1 Global Top Recurrent Glioblastoma Multiforme (GBM) Treatment Players by Revenue (2017-2022)
        3.1.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Players (2017-2022)
    3.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue
    3.4 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Concentration Ratio
        3.4.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue in 2021
    3.5 Recurrent Glioblastoma Multiforme (GBM) Treatment Key Players Head office and Area Served
    3.6 Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Product Solution and Service
    3.7 Date of Enter into Recurrent Glioblastoma Multiforme (GBM) Treatment Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Recurrent Glioblastoma Multiforme (GBM) Treatment Breakdown Data by Type
    4.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Historic Market Size by Type (2017-2022)
    4.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Forecasted Market Size by Type (2023-2028)
5 Recurrent Glioblastoma Multiforme (GBM) Treatment Breakdown Data by Application
    5.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Historic Market Size by Application (2017-2022)
    5.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2017-2028)
    6.2 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type
        6.2.1 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2017-2022)
        6.2.2 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2023-2028)
        6.2.3 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Type (2017-2028)
    6.3 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application
        6.3.1 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2017-2022)
        6.3.2 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2023-2028)
        6.3.3 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application (2017-2028)
    6.4 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country
        6.4.1 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2017-2022)
        6.4.2 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2023-2028)
        6.4.3 U.S.
        6.4.4 Canada
7 Europe
    7.1 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2017-2028)
    7.2 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type
        7.2.1 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2017-2022)
        7.2.2 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2023-2028)
        7.2.3 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Type (2017-2028)
    7.3 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application
        7.3.1 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2017-2022)
        7.3.2 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2023-2028)
        7.3.3 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application (2017-2028)
    7.4 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country
        7.4.1 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2017-2022)
        7.4.2 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2023-2028)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2017-2028)
    8.2 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type
        8.2.1 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2017-2022)
        8.2.2 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2023-2028)
        8.2.3 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Type (2017-2028)
    8.3 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application
        8.3.1 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2017-2022)
        8.3.2 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2023-2028)
        8.3.3 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application (2017-2028)
    8.4 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Region
        8.4.1 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Region (2017-2022)
        8.4.2 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Region (2023-2028)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia 
9 Latin America
    9.1 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2017-2028)
    9.2 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type
        9.2.1 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2017-2022)
        9.2.2 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2023-2028)
        9.2.3 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Type (2017-2028)
    9.3 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application
        9.3.1 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2017-2022)
        9.3.2 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2023-2028)
        9.3.3 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application (2017-2028)
    9.4 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country
        9.4.1 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2017-2022)
        9.4.2 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2023-2028)
        9.4.3 Mexico
        9.4.4 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2017-2028)
    10.2 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type
        10.2.1 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2017-2022)
        10.2.2 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2023-2028)
        10.2.3 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Type (2017-2028)
    10.3 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application
        10.3.1 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2017-2022)
        10.3.2 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2023-2028)
        10.3.3 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application (2017-2028)
    10.4 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country
        10.4.1 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2017-2022)
        10.4.2 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2023-2028)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE
11 Key Players Profiles
    11.1 Astrazeneca
        11.1.1 Astrazeneca Company Details
        11.1.2 Astrazeneca Business Overview
        11.1.3 Astrazeneca Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
        11.1.4 Astrazeneca Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2017-2022)
        11.1.5 Astrazeneca Recent Developments
    11.2 Roche
        11.2.1 Roche Company Details
        11.2.2 Roche Business Overview
        11.2.3 Roche Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
        11.2.4 Roche Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2017-2022)
        11.2.5 Roche Recent Developments
    11.3 GlaxoSmithKline
        11.3.1 GlaxoSmithKline Company Details
        11.3.2 GlaxoSmithKline Business Overview
        11.3.3 GlaxoSmithKline Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
        11.3.4 GlaxoSmithKline Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2017-2022)
        11.3.5 GlaxoSmithKline Recent Developments
    11.4 Merck
        11.4.1 Merck Company Details
        11.4.2 Merck Business Overview
        11.4.3 Merck Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
        11.4.4 Merck Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2017-2022)
        11.4.5 Merck Recent Developments
    11.5 Pfizer
        11.5.1 Pfizer Company Details
        11.5.2 Pfizer Business Overview
        11.5.3 Pfizer Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
        11.5.4 Pfizer Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2017-2022)
        11.5.5 Pfizer Recent Developments
    11.6 AngioChem
        11.6.1 AngioChem Company Details
        11.6.2 AngioChem Business Overview
        11.6.3 AngioChem Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
        11.6.4 AngioChem Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2017-2022)
        11.6.5 AngioChem Recent Developments
    11.7 Vascular Biogeneics
        11.7.1 Vascular Biogeneics Company Details
        11.7.2 Vascular Biogeneics Business Overview
        11.7.3 Vascular Biogeneics Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
        11.7.4 Vascular Biogeneics Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2017-2022)
        11.7.5 Vascular Biogeneics Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Author Details
    13.3 Disclaimer

List of Tables
    Table 1. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
    Table 2. Key Players of Oral Medications
    Table 3. Key Players of Temozolomide
    Table 4. Key Players of Radiosensitizers
    Table 5. Key Players of Nitrosoureas Drugs
    Table 6. Key Players of Radiation Therapy
    Table 7. Key Players of Chemotherapy
    Table 8. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
    Table 9. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 10. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Region (2017-2022) & (US$ Million)
    Table 11. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Region (2017-2022)
    Table 12. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 13. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Region (2023-2028)
    Table 14. Recurrent Glioblastoma Multiforme (GBM) Treatment Market Trends
    Table 15. Recurrent Glioblastoma Multiforme (GBM) Treatment Market Drivers
    Table 16. Recurrent Glioblastoma Multiforme (GBM) Treatment Market Challenges
    Table 17. Recurrent Glioblastoma Multiforme (GBM) Treatment Market Restraints
    Table 18. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Players (2017-2022) & (US$ Million)
    Table 19. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Share by Players (2017-2022)
    Table 20. Global Top Recurrent Glioblastoma Multiforme (GBM) Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment as of 2021)
    Table 21. Ranking of Global Top Recurrent Glioblastoma Multiforme (GBM) Treatment Companies by Revenue (US$ Million) in 2021
    Table 22. Global 5 Largest Players Market Share by Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue (CR5 and HHI) & (2017-2022)
    Table 23. Key Players Headquarters and Area Served
    Table 24. Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Product Solution and Service
    Table 25. Date of Enter into Recurrent Glioblastoma Multiforme (GBM) Treatment Market
    Table 26. Mergers & Acquisitions, Expansion Plans
    Table 27. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2017-2022) & (US$ Million)
    Table 28. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Type (2017-2022)
    Table 29. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 30. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Type (2023-2028)
    Table 31. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2017-2022) & (US$ Million)
    Table 32. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Share by Application (2017-2022)
    Table 33. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 34. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Share by Application (2023-2028)
    Table 35. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2017-2022) & (US$ Million)
    Table 36. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2023-2028) & (US$ Million)
    Table 37. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2017-2022) & (US$ Million)
    Table 38. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2023-2028) & (US$ Million)
    Table 39. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2017-2022) & (US$ Million)
    Table 40. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2023-2028) & (US$ Million)
    Table 41. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2017-2022) & (US$ Million)
    Table 42. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2023-2028) & (US$ Million)
    Table 43. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2017-2022) & (US$ Million)
    Table 44. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2023-2028) & (US$ Million)
    Table 45. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2017-2022) & (US$ Million)
    Table 46. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2023-2028) & (US$ Million)
    Table 47. Asia Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2017-2022) & (US$ Million)
    Table 48. Asia Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2023-2028) & (US$ Million)
    Table 49. Asia Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2017-2022) & (US$ Million)
    Table 50. Asia Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2023-2028) & (US$ Million)
    Table 51. Asia Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Region (2017-2022) & (US$ Million)
    Table 52. Asia Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Region (2023-2028) & (US$ Million)
    Table 53. Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2017-2022) & (US$ Million)
    Table 54. Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2023-2028) & (US$ Million)
    Table 55. Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2017-2022) & (US$ Million)
    Table 56. Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2023-2028) & (US$ Million)
    Table 57. Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2017-2022) & (US$ Million)
    Table 58. Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2023-2028) & (US$ Million)
    Table 59. Middle East and Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2017-2022) & (US$ Million)
    Table 60. Middle East and Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2023-2028) & (US$ Million)
    Table 61. Middle East and Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2017-2022) & (US$ Million)
    Table 62. Middle East and Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2023-2028) & (US$ Million)
    Table 63. Middle East and Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2017-2022) & (US$ Million)
    Table 64. Middle East and Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2023-2028) & (US$ Million)
    Table 65. Astrazeneca Company Details
    Table 66. Astrazeneca Business Overview
    Table 67. Astrazeneca Recurrent Glioblastoma Multiforme (GBM) Treatment Product
    Table 68. Astrazeneca Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2017-2022) & (US$ Million)
    Table 69. Astrazeneca Recent Developments
    Table 70. Roche Company Details
    Table 71. Roche Business Overview
    Table 72. Roche Recurrent Glioblastoma Multiforme (GBM) Treatment Product
    Table 73. Roche Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2017-2022) & (US$ Million)
    Table 74. Roche Recent Developments
    Table 75. GlaxoSmithKline Company Details
    Table 76. GlaxoSmithKline Business Overview
    Table 77. GlaxoSmithKline Recurrent Glioblastoma Multiforme (GBM) Treatment Product
    Table 78. GlaxoSmithKline Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2017-2022) & (US$ Million)
    Table 79. GlaxoSmithKline Recent Developments
    Table 80. Merck Company Details
    Table 81. Merck Business Overview
    Table 82. Merck Recurrent Glioblastoma Multiforme (GBM) Treatment Product
    Table 83. Merck Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2017-2022) & (US$ Million)
    Table 84. Merck Recent Developments
    Table 85. Pfizer Company Details
    Table 86. Pfizer Business Overview
    Table 87. Pfizer Recurrent Glioblastoma Multiforme (GBM) Treatment Product
    Table 88. Pfizer Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2017-2022) & (US$ Million)
    Table 89. Pfizer Recent Developments
    Table 90. AngioChem Company Details
    Table 91. AngioChem Business Overview
    Table 92. AngioChem Recurrent Glioblastoma Multiforme (GBM) Treatment Product
    Table 93. AngioChem Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2017-2022) & (US$ Million)
    Table 94. AngioChem Recent Developments
    Table 95. Vascular Biogeneics Company Details
    Table 96. Vascular Biogeneics Business Overview
    Table 97. Vascular Biogeneics Recurrent Glioblastoma Multiforme (GBM) Treatment Product
    Table 98. Vascular Biogeneics Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2017-2022) & (US$ Million)
    Table 99. Vascular Biogeneics Recent Developments
    Table 100. Research Programs/Design for This Report
    Table 101. Key Data Information from Secondary Sources
    Table 102. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Type: 2021 VS 2028
    Figure 2. Oral Medications Features
    Figure 3. Temozolomide Features
    Figure 4. Radiosensitizers Features
    Figure 5. Nitrosoureas Drugs Features
    Figure 6. Radiation Therapy Features
    Figure 7. Chemotherapy Features
    Figure 8. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application: 2021 VS 2028
    Figure 9. Hospitals Case Studies
    Figure 10. Clinics Case Studies
    Figure 11. Ambulatory Surgical Centers Case Studies
    Figure 12. Recurrent Glioblastoma Multiforme (GBM) Treatment Report Years Considered
    Figure 13. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 14. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 15. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Region: 2021 VS 2028
    Figure 16. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Players in 2021
    Figure 17. Global Top Recurrent Glioblastoma Multiforme (GBM) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment as of 2021)
    Figure 18. The Top 10 and 5 Players Market Share by Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue in 2021
    Figure 19. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY (2017-2028) & (US$ Million)
    Figure 20. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Market Share by Type (2017-2028)
    Figure 21. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Market Share by Application (2017-2028)
    Figure 22. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Share by Country (2017-2028)
    Figure 23. United States Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 24. Canada Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 25. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY (2017-2028) & (US$ Million)
    Figure 26. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Market Share by Type (2017-2028)
    Figure 27. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Market Share by Application (2017-2028)
    Figure 28. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Share by Country (2017-2028)
    Figure 29. Germany Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 30. France Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 31. U.K. Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 32. Italy Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 33. Russia Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 34. Nordic Countries Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 35. Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY (2017-2028) & (US$ Million)
    Figure 36. Asia Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Market Share by Type (2017-2028)
    Figure 37. Asia Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Market Share by Application (2017-2028)
    Figure 38. Asia Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Share by Region (2017-2028)
    Figure 39. China Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 40. Japan Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 41. South Korea Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 42. Southeast Asia Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 43. India Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 44. Australia Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
    Figure 45. Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY (2017-2028) & (US$ Million)
    Figure 46. Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Market Share by Type (2017-2028)
    Figure 47. Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Market Share by Application (2017-2028)
    Figure 48. Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Share by Country (2017-2028)
    Figure 49. Mexico Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 50. Brazil Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 51. Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY (2017-2028) & (US$ Million)
    Figure 52. Middle East and Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Market Share by Type (2017-2028)
    Figure 53. Middle East and Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Market Share by Application (2017-2028)
    Figure 54. Middle East and Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Share by Country (2017-2028)
    Figure 55. Turkey Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 56. Saudi Arabia Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 57. UAE Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 58. Astrazeneca Revenue Growth Rate in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2017-2022)
    Figure 59. Roche Revenue Growth Rate in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2017-2022)
    Figure 60. GlaxoSmithKline Revenue Growth Rate in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2017-2022)
    Figure 61. Merck Revenue Growth Rate in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2017-2022)
    Figure 62. Pfizer Revenue Growth Rate in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2017-2022)
    Figure 63. AngioChem Revenue Growth Rate in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2017-2022)
    Figure 64. Vascular Biogeneics Revenue Growth Rate in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2017-2022)
    Figure 65. Bottom-up and Top-down Approaches for This Report
    Figure 66. Data Triangulation
    Figure 67. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Astrazeneca
Roche
GlaxoSmithKline
Merck
Pfizer
AngioChem
Vascular Biogeneics
Frequently Asked Questions
Recurrent Glioblastoma Multiforme (GBM) Treatment report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Recurrent Glioblastoma Multiforme (GBM) Treatment report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Recurrent Glioblastoma Multiforme (GBM) Treatment report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Recycled Plastic

Recycled Plastic market is segmented by Type and by Application. Players, stakeholders, and other ... Read More

Recycled Steel

Recycled Steel market is segmented by Type and by Application. Players, stakeholders, and other p ... Read More

Red Algae

Red Algae market is segmented by Type and by Application. Players, stakeholders, and other partic ... Read More

Red Clover

Red Clover market is segmented by Type and by Application. Players, stakeholders, and other parti ... Read More